Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates

26.07.2022 - LC-FAOD program to move forward into the next stage of clinical developmentEnrollment of pivotal STRIDE study in primary mitochondrial myopathies (PMM) patients with mitochondrial DNA (mtDNA) defects on track to be completed year-end 2022Alignment ...

Related Keywords

Alejandro Dorenbaum ,Gregoryj Flesher ,Joyce Allaire ,Exchange Commission ,Reneo Pharmaceuticals ,Lifesci Advisors ,Energy Fatigue ,Item Short Form Health Survey ,Reneo Pharmaceuticals Inc ,Young ,Modified Fatigue Impact Scale ,Chief Medical Officer ,Private Securities Litigation Reform Act ,Sci Advisors ,